These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21688207)

  • 1. Azacitidine adverse effects in patients with myelodysplastic syndromes.
    San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects of azacitidine: onset, duration, and treatment.
    Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():1-5. PubMed ID: 21688206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
    Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
    J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP; Stone RM
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
    Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
    Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
    Prescrire Int; 2011 Feb; 20(113):40. PubMed ID: 21488589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
    Voso MT; Fianchi L; Criscuolo M; Greco M; D'Alo F; Hohaus S; Pagano L; Leone G
    Leuk Res; 2012 Jan; 36(1):e15-7. PubMed ID: 21907408
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
    Issa JP
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
    Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G
    Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of azacitidine in myelodysplastic syndromes.
    Vigil CE; Martin-Santos T; Garcia-Manero G
    Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
    Marcucci G; Silverman L; Eller M; Lintz L; Beach CL
    J Clin Pharmacol; 2005 May; 45(5):597-602. PubMed ID: 15831784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome.
    Hueser CN; Patel AJ
    Pharmacotherapy; 2007 Dec; 27(12):1759-62. PubMed ID: 18041893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Azacytidine for the treatment of myelodysplastic syndromes.
    Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
    Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
    Almeida AM; Pierdomenico F
    Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.
    Cseh AM; Niemeyer CM; Yoshimi A; Catala A; Frühwald MC; Hasle H; van den Heuvel-Eibrink MM; Lauten M; De Moerloose B; Smith OP; Bernig T; Gruhn B; Kulozik AE; Metzler M; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
    Br J Haematol; 2016 Mar; 172(6):930-6. PubMed ID: 26766110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine dosage in myelodysplastic syndromes.
    Giagounidis AA
    Blood; 2007 Aug; 110(3):1082-3; author reply 1083. PubMed ID: 17644750
    [No Abstract]   [Full Text] [Related]  

  • 20. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.